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When the terminal amino group in the side chain of primaquine was blocked with an ethoxyacetyl group 
shown in 2, or eliminated by oxidative deamination tocarboxylic acid 3, the antimalarial effect was marked- 
ly reduced in a screening assay which measures tissue schizonticidal ctivity. The optical isomers 1A and 
1B of primaquine had similar antimalarial potency to the racemic mixture but 1B appeared less toxic. The 
5-phenoxy-substituted analogue 4, belonging to a new class of antimalarials, howed similar potency in the 
assays to either 1A or IB but seemed less cytotoxic than (_+)-primaquine. Compounds 1A and 1B were 
found to be competitive inhibitors of human monoamine oxidase (MAO) A and B (Ki range 103-225/zM), 
but 4 showed 10-30-fold greater competitive inhibition of MAO A (Ki =6.8/~M) and 40-90-fold greater 
non-competitive inhibition of MAO B (Ki = 2.3 pM). 
Monoamine oxidase; Primaquine; Antimalarial activity; Enzyme inhibition 
1. INTRODUCTION 
(_+)-Primaquine (1), an 8-aminoquinoline, is 
presently the only tissue schizontocide available 
for the radical treatment of Plasmodium vivax and 
P. ovale infections. Its usefulness is offset by in- 
herent toxicity, resulting from methaemo- 
globinaemia and haemolysis in patients with 
glucose 6-phosphate deficiency. Recent research 
on primaquine conducted by Chemal [l] led to the 
discovery of two metabolic pathways, one affec- 
ting the aromatic ring A, the other the 8-N- 
aminobutyl chain of primaquine. The second 
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pathway, originally discovered in bacteria [2], 
resulted in the formation of N-acetylprimaquine 
and a desaminocarboxylic a id 2, later found to 
represent a major metabolite of primaquine in rat, 
hamster and monkey [3], as well as humans [4,5]. 
The testing of tissue schizontocidal activity of 
antimalarials has been greatly facilitated by a novel 
in vitro assay, evaluating exo-erythrocytic s hizon- 
tocides in primary cultures of hepatocytes [6]. 
Since little is known regarding the mechanism of 
action of primaquine and its toxicity, we decided 
to evaluate in vitro schizontocidal activity and 
cytotoxicity of several key compounds chemically 
related to primaquine by the new assay method. 
The conversion of primaquine into metabolite 3, 
could in principle be achieved through oxidative 
deamination by monoamine oxidases A and B 
(MAO A and B). Therefore, these compounds 
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Fig.l. Compounds 2, 3 and 4 are racemic mixtures. 
Compounds 1A and 1B were assayed as diphosphate 
salts, compound 4 as citrate salt and compound 2 as a 
monophosphate salt. 
were also tested as inhibitors of highly purified 
human placental MAO A [7] and human liver 
MAO B [8] as an initial step in assaying the interac- 
tion of primaquines with these amine-degrading 
enzymes. 
Chosen for this study were (+)-  and ( - ) -  
primaquine ( IA and 1B), the two optical isomers 
of primaquine of still unknown configuration [9], 
(+)-N-ethoxyacetylprimaquine 2 [10], an N- 
acylated primaquine resembling the bacterial 
metabolite (+_)-N-acetylprimaquine [2], (___)- 
carboxy-metabolite 3 obtained by total synthesis 
[11], and (___)-5-(m-trifluorophenoxy)primaquine 
(4), a representative of a superior class of 
primaquine-related antimalarials [12]. 
2. MATERIALS AND METHODS 
( + )- and ( - )-primaquine diphosphate 
(1A.2H3PO4 and 1B.2H3PO4) and (+_)-5-(m- 
trifluoromethylphenoxy)primaquine citrate (4. 
C6H807) were obtained from Dr D. Klayman, 
Walter Reed Institute of Research, Washington, 
DC. (+)-Desaminocarboxyprimaquine (3) was ob- 
tained from Dr J. McChesney, School of Phar- 
macy, University of Mississippi, University, MS, 
and (_)-N-ethoxyacetylprimaquine (2) was 
prepared as in [10]. 
The strain used in the assay was P. yoelii 
265 BY, isolated from Thamnornys rutilans cap- 
tured in the Central African Republic in 1969. The 
vector Anopheles stephensi originated from a col- 
ony established by Shute and Maryon [13] in 
Table 1 
In vitro schizontocidal ctivity of compounds related to 
primaquine 
Compound Schizontocidal ctivity 
IDs0 ID90 
1 0.03 0.1 
1A 0.03 0.1 
1B 0.2 0.8 
4 0.2 0.8 
3 30 50 
2 3 40 
England. Cell cultures were primary cultures of 
laboratory-bred T. gazellae hepatocytes, cultivated 
as discs of 5 mm diameter [6,14]. Tests were per- 
formed on petri dishes measuring 35 mm in 
diameter each, with two discs of hepatocytes. The 
compounds were dissolved in 1 ml MEM culture 
medium (Gibco) complemented with NaHCO3 
(2.2 mg/ml), bovine albumin (2 mg/ml), insulin 
(10 mg/ml), fetal calf serum (10%), penicillin 
(200 IU/ml),  streptomycin (0.2 mg/ml) and 
hydrocortisone (3.5 × 10 -5 M), added to cultures 
2 h after the addition of sporozoites, and solutions 
renewed after 24 h. Each drug concentration was 
tested in 3 petri dishes (6 discs), 3 infected petri 
dishes kept as untreated controls and 3 others 
treated with primaquine diphosphate at 0.1 rag/1 
(LD9o) and cultures fixed with methanol after 48 h 
[6,14]. At that time the size of the schizonts vary- 
ing between 20 and 40 #m parasites were counted 
with a 20 × objective. ID5o and ID9o values were 
calculated by the graphic method of Trevan [15]. 
Dead cells were counted after vital staining with 
trypan blue. Compounds also were tested as in- 
hibitors of highly purified human liver MAO B [8] 
and human ~placental MAO A [7] using 
kynuramine as a substrate. 
3. RESULTS 
The results are presented in the form of zones of 
activity and cytotoxicity. (+)-Primaquine (1A) is 
about as active as (+)-primaquine (1) and only 
slightly less toxic. ( - ) -Pr imaquine (1B), however, 
is probably both less active and less toxic. There 
does not seem to be any important separation of 
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Fig.2. Zones of schizontocidal ctivity and cytotoxicity 
of primaquine diphosphate and 5 relatives of 
primaquine. (~,~) Zone of schizontocidal ctivity; (A) 
zone of cell toxicity; (zx) cell vacuolation. 
toxicity and activity for the two isomers. Com- 
pounds 2 and 3 were only active at 50 mg/l. The 
cytotoxicity of the compounds tested was dif- 
ferent: 2 and 3 were cytotoxic near the dose giving 
full schizontocidal ctivity, whereas 4 was cytotox- 
ic at doses which were much higher than that re- 
quired for schizontocidal activity. Table 3 
summarizes Ki values and the type of inhibition of 
compounds against MAO A and MAO B. All com- 
pounds tested were found to be competitive in- 
hibitors of MAO A with 4 being the most potent 
(Ki = 6.8/~M). These analogues demonstrated 
similar activity against MAO B with the exception 
of 4, which gave non-competitive inhibition (Ki = 
2.3/~M). 
In vitro cell 
Table 2 
toxicity of 5 compounds related to 
primaquine 
Compound Cell toxicity 
10 -3 10 -2 10 -l 1 10 50 
1 0 0 HT 
1A 0 0 0 V HT 
1B 0 0 0 HT 
4 0 0 0 HT HT 
3 0 0 V 
2 0 0 V 
0, no toxicity; ST, slight toxicity (few dead cells at the 
periphery of the disc of hepatocytes); HT, high toxicity 
(all cells dead); V, no dead ceils, but numerous 
intracytoplasmic vacuoles 
Table 3 
MAO A and B inhibition by primaquines 
Compound Type of inhibition 
MAO A MAO B 
1A competitive competitive 
(225/zM) (193/~M) 
IB competitive competitive 
(125/tM) (103/~M) 
4 competitive non-competitive 
(6.8/~M) (2.3/zM) 
Human liver MAO B and human placental MAO A were 
assayed with 6 different concentrations of kynuramine 
(40-400/zM) in the presence and absence of the 
primaquines to be tested. Values for Km,app and Vmax.app 
were obtained by linear regression analysis of duplicate 
determinations plotted as I /V  vs 1/[S]. Concentrations 
of inhibitors ranged from 0 to 5Ki. Initial reaction rates 
were obtained by monitoring the increase in absorbance 
at 314 nm (4-hydroxyquinoline, EM = 12300 M -~ cm -1) 
using a Beckman DU-7U spectrometer. Reactions were 
carried out in 0.5 ml of 25 mM sodium phosphate buffer 
(pH 7.6) at 30°C and started by the addition of substrate 
4. DISCUSSION 
Compounds 1A, 1B and 4 displayed similar ac- 
tivity in vitro to (+_)-primaquine tested as the 
diphosphate salt. Both, 1B and 4 appeared to be 
less cytotoxic than (+_)-primaquine, with 1B being 
the least toxic of the compounds tested. The active 
concentrations of 2 and 3 were substantially higher 
than those of ( + )-primaquine. The fact that block- 
ing of the primary amino group with an ethox- 
yacetyl group or its elimination by simultaneous 
oxidation of the terminal methylene group to a car- 
boxy group was accompanied by a complete loss of 
antimalarial activity is noteworthy, indicating that 
the terminal primary amino group in the side chain 
of 8-aminoquinoline antimalarials is an essential 
structural feature. The finding of similar and 
relatively moderate inhibition of MAO A and B in 
vitro by 1A and 1B (Ki ranges 103-225/~M), 
enhanced 10-90-fold with 4, does not strongly 
support the concept that MAO A and B could 
catalyze their deamination to 3 in vivo at drug con- 
centrations that give schizontocidal ctivity. Com- 
parison of the optical isomers 1A and 1B of 
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Volume 214, number 2 FEBS LETTERS April 1987 
primaquine, favouring here the ( - )  isomer 1B as 
the less toxic compound, is offset by earlier reports 
showing that the (+)  isomer 1A had a better 
therapeutic index in rhesus monkeys [16], with 
both 1A and 1B similarly inhibiting drug 
metabolism [17]. In view of the appearance of new 
and much improved antimalarials for radical cure 
and clearing of tissue parasites, such as 4 [12] or its 
4-methyl-substituted analogues [18], further 
development of either ( - ) -pr imaquine (1B) or its 
(+)  isomer 1A does in our opinion not seem war- 
ranted. However, the question regarding dif- 
ferences in activity and toxicity of optical isomers 
of the new generation of analogues should be 
pursued. 
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